Novel anti-PD-L1/IL-15 fusion protein enhances immunological activity against tumor cells Dec. 17, 2014
Antitumor activity seen with HER2-T-cell-dependent bispecific antibody developed at Genentech Dec. 16, 2014
Safety data presented for onartuzumab plus bevacizumab combination therapy in recurrent glioblastoma Dec. 15, 2014
RSS